ClinicalTrials.gg
Status unknownNCT03746288Updated Nov 19, 2018

To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)

A Phase 2 interventional study of CAN008 in GBM, sponsored by CANbridge Life Sciences Ltd.. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by CANbridge Life Sciences Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a multicenter, randomized, controlled study, aiming to evaluate the efficacy and safety of CAN008 administered once-weekly with rRT for treating first tumor recurrence in patients with GBM.

Read the detailed description

This is a multi-center, randomized, controlled clinical trial to evaluate the efficacy and safety of CAN008 administered once-weekly with re-radiation therapy (rRT) in patients with an initial relapse of GBM. The subjects will be randomized into the treatment group (CAN008 + rRT) or the control group (rRT). The investigational treatment can be continued as long as the subjects have experienced lasting clinical benefits (complete response [CR], partial response [PR] or stable disease [SD]).

This study will be carried out in GBM subjects with an initial or second relapse. The subjects must have received standard care, including combination of radiotherapy and TMZ after surgical resection, and must be candidates for re-radiation therapy (rRT).

02

Conditions studied

  • GBM
03

In context

Lead sponsor

CANbridge Life Sciences Ltd. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Primary Inclusion Criteria:

  1. Subjects with diagnosed GBM confirmed by pathological tests at the central laboratory;
  2. Subjects who have definite CD95L IHC expression level and CD95L methylation level results confirmed at the central laboratory;
  3. Subjects with GBM who are not suitable for surgical ablation after tumor recurrence or have residual neoplasm after surgical ablation;
  4. Patients with disease progression or recurrence based on RANO (Response Assessment in Neuro-oncology) Criteria identified upon magnetic resonance imaging (MRI) performed two weeks prior to the first dose of drug and two weeks prior to the initiation of rRT;
  5. Age ≥ 18 years and ≤ 70 years;
  6. Expected survival ≥ 3 months;
  7. score ≥60;
  8. Subjects who have tumor progression after having previously received standard treatments including surgery, chemoradiation combination (RT+ TMZ), chemotherapy (TMZ);
  9. Subjects who have a single primary lesion or have scattered or multiple lesions which can be contained within a radiation target volume;
  10. Subjects who have received a maximum dose of 60 Gy for a single tumor in situ in the previous RT, or have not received RT for at least 8 months;
  11. Subjects eligible to receive rRT who have recurrence of tumor in situ on the T1-weighted MRI (T1-MRI) (Gd), with the maximum diameter of 1-4 cm;
  12. Subjects who have appropriate hematologic parameters ( (ANC) ≥1.5×109/L, count ≥80×109/L, (Hb)≥90 g/L), kidney function (serum creatinine≤1.25×) and liver function (total ≤1. 5×ULN, ≤2.5×ULN and ALT≤2.5×ULN);
  13. Subjects treated with hormone therapy must receive the treatment with hormones at a stable dose or a reduced dose within 5 days before entering the trial;
  14. Female subjects of must have a negative serum HCG pregnancy test within 7 days before the first dose of investigational drug;
  15. Male and female subjects of childbearing potential must agree to adopt approved methods (such as condoms and intrauterine ring) during the trial and till 3 months after the completion of this trial;
  16. Subjects who are willing and able to comply with regulations specified in the clinical trial protocol (as judged by investigators);
  17. Subjects who have signed the Form (ICF);

Primary Exclusion Criteria:

  1. Subjects who have previously received more than one course of RT for the head or have received a total dose of >60 Gy in the previous RT;
  2. Subjects who have received an accumulated radiation dose of >54 Gy for the optic chiasma;
  3. Subjects whose scattered or multiple tumors cannot be included within a radiation target volume;
  4. Subjects who have previously received treatment with bevacizumab, iodine radiotherapy, gamma knife and/or brachytherapy;
  5. Subjects who cannot undergo MRI examination or follow-ups;
  6. Subjects with (HIV) infection;
  7. Subjects with active viral hepatitis need to be excluded:

    • For those with inactive viral hepatitis, they can be considered to be enrolled in this trial if their liver function is within the allowable range, that is, virus deoxyribonucleic acid (HBV- DNA)\<2,000 IU/Ml;
    • For those infected with virus (HCV), they can also be considered to be included if no HCV ribonucleic acid (HCV-RNA) is detected;
  8. Subjects who have hereditary fructose intolerance (HFI);
  9. Subjects whose previous history (such as serious coronary heart disease, serious diabetes, immune deficiency, sequelae of apoplexia, serious mental retardation, etc.) is considered to indicate poor prognosis, as evaluated by investigators;
  10. Pregnant and breast-feeding women;
  11. Subjects who suffer from any malignant tumors (except for basal cell carcinoma or cervical carcinoma in situ) at the same time. Those who have previously suffered from malignant tumors but have no evidences of disease recurrence for at least 5 years can still participate in this trial;
  12. Subjects who have participated in other clinical trials within 30 days prior to the enrollment or during the treatment phase of this trial;
  13. Subjects who has known coronary heart disease complicated by serious cardiac arrhythmias or heart failure ( III-IV).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day

    Drug: CAN008

  • Active comparator
    Control Group

    The dose is 2.0 Gy/d, 5 times/week, with a total planned radiation dose of 36 Gy.

    Drug: CAN008

Interventions

  • DrugCAN008

    CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day

    Also known as: Radiation

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: From date of randomization until the date of death from any cause,assessed up to 12 months

Secondary outcomes

  1. Progression free survival (PFS)

    Time frame: "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months

  2. 6-month progression free survival rate (PFS6)

    Time frame: The percentage of subjects confirmed without PD or death at 6 months after randomization.

  3. Objective response rate (ORR)

    Time frame: rom date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 8 months").

  4. Duration of response (DOR)

    Time frame: rom date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 8 months").

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2018; primary completion for Jul 2021, 31 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2018
First posted
Nov 19, 2018
StartEst.
Nov 20, 2018
Primary completionEst.
Jul 1, 2021
CompletionEst.
Dec 31, 2021
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03746288
Lead sponsor
CANbridge Life Sciences Ltd.
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Nov 20, 2018 (estimated)
Primary completion
Jul 1, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Nov 19, 2018

Study contacts

Wenbin Li
Contact
neure55@126.com
86-010-67096611

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APG101

Start the discussion